On Tuesday, Prime Medicine Inc (NASDAQ: PRME) opened lower -3.61% from the last session, before settling in for the closing price of $1.66. Price fluctuations for PRME have ranged from $1.12 to $8.27 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -20.00% over the past five years. Company’s average yearly earnings per share was noted 27.67% at the time writing. With a float of $51.92 million, this company’s outstanding shares have now reached $131.16 million.
Let’s look at the performance matrix of the company that is accounted for 214 employees. In terms of profitability, gross margin is 98.55%, operating margin of -496.77%, and the pretax margin is -480.61%.
Prime Medicine Inc (PRME) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Prime Medicine Inc is 60.42%, while institutional ownership is 33.67%.
Prime Medicine Inc (PRME) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.32 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 27.67% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 12.59% during the next five years compared to -124.13% drop over the previous five years of trading.
Prime Medicine Inc (NASDAQ: PRME) Trading Performance Indicators
Check out the current performance indicators for Prime Medicine Inc (PRME). In the past quarter, the stock posted a quick ratio of 5.58. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 70.42.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.70, a number that is poised to hit -0.31 in the next quarter and is forecasted to reach -1.12 in one year’s time.
Technical Analysis of Prime Medicine Inc (PRME)
Prime Medicine Inc (NASDAQ: PRME) saw its 5-day average volume 1.36 million, a positive change from its year-to-date volume of 1.29 million. As of the previous 9 days, the stock’s Stochastic %D was 68.18%. Additionally, its Average True Range was 0.19.
During the past 100 days, Prime Medicine Inc’s (PRME) raw stochastic average was set at 19.60%, which indicates a significant decrease from 65.10% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 119.84% in the past 14 days, which was higher than the 99.55% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.9422, while its 200-day Moving Average is $3.2980. Nevertheless, the first resistance level for the watch stands at $1.6700 in the near term. At $1.7400, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.7900. If the price goes on to break the first support level at $1.5500, it is likely to go to the next support level at $1.5000. Assuming the price breaks the second support level, the third support level stands at $1.4300.
Prime Medicine Inc (NASDAQ: PRME) Key Stats
There are currently 131,161K shares outstanding in the company with a market cap of 209.86 million. Presently, the company’s annual sales total 2,980 K according to its annual income of -195,880 K. Last quarter, the company’s sales amounted to 2,180 K and its income totaled -42,280 K.
